S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma

PURPOSE: Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patien...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Onco Targets Ther
Glavni autori: Katono, Ken, Sato, Yuichi, Kobayashi, Makoto, Nagashio, Ryo, Ryuge, Shinichiro, Igawa, Satoshi, Ichinoe, Masaaki, Murakumo, Yoshiki, Saegusa, Makoto, Masuda, Noriyuki
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679695/
https://ncbi.nlm.nih.gov/pubmed/29138580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145072
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items